Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect

Guido Veit, Kathryn Oliver, Pirjo Apaja, Doranda Perdomo, Aurélien Bidaud-Meynard, Sheng Ting Lin, Jingyu Guo, Mert Icyuz, Eric J. Sorscher, John L. Hartman IV, Gergely L. Lukacs

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The most common cystic fibrosis (CF) causing mutation, deletion of phenylalanine 508 (ΔF508 or Phe508del), results in functional expression defect of the CF transmembrane conductance regulator (CFTR) at the apical plasma membrane (PM) of secretory epithelia, which is attributed to the degradation of the misfolded channel at the endoplasmic reticulum (ER). Deletion of phenylalanine 670 (ΔF670) in the yeast oligomycin resistance 1 gene (YOR1, an ABC transporter) of Saccharomyces cerevisiae phenocopies the ΔF508-CFTR folding and trafficking defects. Genome-wide phenotypic (phenomic) analysis of the Yor1-ΔF670 biogenesis identified several modifier genes of mRNA processing and translation, which conferred oligomycin resistance to yeast. Silencing of orthologues of these candidate genes enhanced the ΔF508-CFTR functional expression at the apical PM in human CF bronchial epithelia. Although knockdown of RPL12, a component of the ribosomal stalk, attenuated the translational elongation rate, it increased the folding efficiency as well as the conformational stability of the ΔF508-CFTR, manifesting in 3-fold augmented PM density and function of the mutant. Combination of RPL12 knockdown with the corrector drug, VX-809 (lumacaftor) restored the mutant function to ~50% of the wild-type channel in primary CFTRΔF508/ΔF508 human bronchial epithelia. These results and the observation that silencing of other ribosomal stalk proteins partially rescue the loss-of-function phenotype of ΔF508-CFTR suggest that the ribosomal stalk modulates the folding efficiency of the mutant and is a potential therapeutic target for correction of the ΔF508-CFTR folding defect.

LanguageEnglish
Article numbere1002462
JournalPLoS Biology
Volume14
Issue number5
DOIs
Publication statusPublished - 11 May 2016
Externally publishedYes

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Veit, G., Oliver, K., Apaja, P., Perdomo, D., Bidaud-Meynard, A., Lin, S. T., ... Lukacs, G. L. (2016). Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect. PLoS Biology, 14(5), [e1002462]. https://doi.org/10.1371/journal.pbio.1002462
Veit, Guido ; Oliver, Kathryn ; Apaja, Pirjo ; Perdomo, Doranda ; Bidaud-Meynard, Aurélien ; Lin, Sheng Ting ; Guo, Jingyu ; Icyuz, Mert ; Sorscher, Eric J. ; Hartman IV, John L. ; Lukacs, Gergely L. / Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect. In: PLoS Biology. 2016 ; Vol. 14, No. 5.
@article{b8637f35138d45f59810d7a147409957,
title = "Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect",
abstract = "The most common cystic fibrosis (CF) causing mutation, deletion of phenylalanine 508 (ΔF508 or Phe508del), results in functional expression defect of the CF transmembrane conductance regulator (CFTR) at the apical plasma membrane (PM) of secretory epithelia, which is attributed to the degradation of the misfolded channel at the endoplasmic reticulum (ER). Deletion of phenylalanine 670 (ΔF670) in the yeast oligomycin resistance 1 gene (YOR1, an ABC transporter) of Saccharomyces cerevisiae phenocopies the ΔF508-CFTR folding and trafficking defects. Genome-wide phenotypic (phenomic) analysis of the Yor1-ΔF670 biogenesis identified several modifier genes of mRNA processing and translation, which conferred oligomycin resistance to yeast. Silencing of orthologues of these candidate genes enhanced the ΔF508-CFTR functional expression at the apical PM in human CF bronchial epithelia. Although knockdown of RPL12, a component of the ribosomal stalk, attenuated the translational elongation rate, it increased the folding efficiency as well as the conformational stability of the ΔF508-CFTR, manifesting in 3-fold augmented PM density and function of the mutant. Combination of RPL12 knockdown with the corrector drug, VX-809 (lumacaftor) restored the mutant function to ~50{\%} of the wild-type channel in primary CFTRΔF508/ΔF508 human bronchial epithelia. These results and the observation that silencing of other ribosomal stalk proteins partially rescue the loss-of-function phenotype of ΔF508-CFTR suggest that the ribosomal stalk modulates the folding efficiency of the mutant and is a potential therapeutic target for correction of the ΔF508-CFTR folding defect.",
author = "Guido Veit and Kathryn Oliver and Pirjo Apaja and Doranda Perdomo and Aur{\'e}lien Bidaud-Meynard and Lin, {Sheng Ting} and Jingyu Guo and Mert Icyuz and Sorscher, {Eric J.} and {Hartman IV}, {John L.} and Lukacs, {Gergely L.}",
year = "2016",
month = "5",
day = "11",
doi = "10.1371/journal.pbio.1002462",
language = "English",
volume = "14",
journal = "PLoS Biology",
issn = "1544-9173",
publisher = "Public Library of Science",
number = "5",

}

Veit, G, Oliver, K, Apaja, P, Perdomo, D, Bidaud-Meynard, A, Lin, ST, Guo, J, Icyuz, M, Sorscher, EJ, Hartman IV, JL & Lukacs, GL 2016, 'Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect', PLoS Biology, vol. 14, no. 5, e1002462. https://doi.org/10.1371/journal.pbio.1002462

Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect. / Veit, Guido; Oliver, Kathryn; Apaja, Pirjo; Perdomo, Doranda; Bidaud-Meynard, Aurélien; Lin, Sheng Ting; Guo, Jingyu; Icyuz, Mert; Sorscher, Eric J.; Hartman IV, John L.; Lukacs, Gergely L.

In: PLoS Biology, Vol. 14, No. 5, e1002462, 11.05.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect

AU - Veit, Guido

AU - Oliver, Kathryn

AU - Apaja, Pirjo

AU - Perdomo, Doranda

AU - Bidaud-Meynard, Aurélien

AU - Lin, Sheng Ting

AU - Guo, Jingyu

AU - Icyuz, Mert

AU - Sorscher, Eric J.

AU - Hartman IV, John L.

AU - Lukacs, Gergely L.

PY - 2016/5/11

Y1 - 2016/5/11

N2 - The most common cystic fibrosis (CF) causing mutation, deletion of phenylalanine 508 (ΔF508 or Phe508del), results in functional expression defect of the CF transmembrane conductance regulator (CFTR) at the apical plasma membrane (PM) of secretory epithelia, which is attributed to the degradation of the misfolded channel at the endoplasmic reticulum (ER). Deletion of phenylalanine 670 (ΔF670) in the yeast oligomycin resistance 1 gene (YOR1, an ABC transporter) of Saccharomyces cerevisiae phenocopies the ΔF508-CFTR folding and trafficking defects. Genome-wide phenotypic (phenomic) analysis of the Yor1-ΔF670 biogenesis identified several modifier genes of mRNA processing and translation, which conferred oligomycin resistance to yeast. Silencing of orthologues of these candidate genes enhanced the ΔF508-CFTR functional expression at the apical PM in human CF bronchial epithelia. Although knockdown of RPL12, a component of the ribosomal stalk, attenuated the translational elongation rate, it increased the folding efficiency as well as the conformational stability of the ΔF508-CFTR, manifesting in 3-fold augmented PM density and function of the mutant. Combination of RPL12 knockdown with the corrector drug, VX-809 (lumacaftor) restored the mutant function to ~50% of the wild-type channel in primary CFTRΔF508/ΔF508 human bronchial epithelia. These results and the observation that silencing of other ribosomal stalk proteins partially rescue the loss-of-function phenotype of ΔF508-CFTR suggest that the ribosomal stalk modulates the folding efficiency of the mutant and is a potential therapeutic target for correction of the ΔF508-CFTR folding defect.

AB - The most common cystic fibrosis (CF) causing mutation, deletion of phenylalanine 508 (ΔF508 or Phe508del), results in functional expression defect of the CF transmembrane conductance regulator (CFTR) at the apical plasma membrane (PM) of secretory epithelia, which is attributed to the degradation of the misfolded channel at the endoplasmic reticulum (ER). Deletion of phenylalanine 670 (ΔF670) in the yeast oligomycin resistance 1 gene (YOR1, an ABC transporter) of Saccharomyces cerevisiae phenocopies the ΔF508-CFTR folding and trafficking defects. Genome-wide phenotypic (phenomic) analysis of the Yor1-ΔF670 biogenesis identified several modifier genes of mRNA processing and translation, which conferred oligomycin resistance to yeast. Silencing of orthologues of these candidate genes enhanced the ΔF508-CFTR functional expression at the apical PM in human CF bronchial epithelia. Although knockdown of RPL12, a component of the ribosomal stalk, attenuated the translational elongation rate, it increased the folding efficiency as well as the conformational stability of the ΔF508-CFTR, manifesting in 3-fold augmented PM density and function of the mutant. Combination of RPL12 knockdown with the corrector drug, VX-809 (lumacaftor) restored the mutant function to ~50% of the wild-type channel in primary CFTRΔF508/ΔF508 human bronchial epithelia. These results and the observation that silencing of other ribosomal stalk proteins partially rescue the loss-of-function phenotype of ΔF508-CFTR suggest that the ribosomal stalk modulates the folding efficiency of the mutant and is a potential therapeutic target for correction of the ΔF508-CFTR folding defect.

UR - http://www.scopus.com/inward/record.url?scp=84971520499&partnerID=8YFLogxK

U2 - 10.1371/journal.pbio.1002462

DO - 10.1371/journal.pbio.1002462

M3 - Article

VL - 14

JO - PLoS Biology

T2 - PLoS Biology

JF - PLoS Biology

SN - 1544-9173

IS - 5

M1 - e1002462

ER -